BRAF and Miyoshi myopathy: A cornerstone in BRAF-mutated MM managements was the introduction in clinical practice of the ATP-competitive BRAF inhibitors, vemurafenib (PLX4032) and dabrafenib (GSK2118436), proved to determine high response rate in BRAF-mutated MM with meaningful impact on progression free survival (PFS) and overall survival (OS) respect to chemotherapy (i.e., dacarbazine) [34].